Skip to content
OpenCapital
Get started

Wave Life Sciences WVE Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$464.45M+92.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$173.38M-34.4%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$232.19M+23.1%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+67.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$288.29M-45.4%

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%—
Debt / equity0×-0.1×
Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's cash & equivalents?
Wave Life Sciences (WVE) reported cash & equivalents of $544.59M in Q1 2026.
How has Wave Life Sciences's cash & equivalents changed year-over-year?
Wave Life Sciences's cash & equivalents increased by 124.0% year-over-year, from $243.08M to $544.59M.
What is the long-term trend for Wave Life Sciences's cash & equivalents?
Over 5 years (2020 to 2025), Wave Life Sciences's cash & equivalents has grown at a 26.7% compound annual growth rate (CAGR), from $184.5M to $602.07M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.